Ferumoxytol-enhanced MRI in the peripheral vasculature
Authors:
- 1 January 2019
- journal article
- review article
- Published by Elsevier in Clinical Radiology
- Vol. 74 (1) , 37-50
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Ferumoxytol vs. Gadolinium agents for contrast‐enhanced MRI: Thoughts on evolving indications, risks, and benefitsJournal of Magnetic Resonance Imaging, 2017
- Comparison of ferumoxytol‐enhanced MRA with conventional angiography for assessment of severity of transplant renal artery stenosisJournal of Magnetic Resonance Imaging, 2016
- MRI with ferumoxytol: A single center experience of safety across the age spectrumJournal of Magnetic Resonance Imaging, 2016
- Premedication with IV steroids effectively prevented anaphylactic reactions following ferumoxytol given as IV push in hematology and oncology patientsAmerican Journal of Hematology, 2015
- Emerging applications for ferumoxytol as a contrast agent in MRIJournal of Magnetic Resonance Imaging, 2014
- Endovascular iliac rescue technique for complete arterial avulsion after transcatheter aortic valve replacementCatheterization and Cardiovascular Interventions, 2014
- Retrospective assessment of the utility of an iron‐based agent for contrast‐enhanced magnetic resonance venography in patients with endstage renal diseasesJournal of Magnetic Resonance Imaging, 2013
- Ferumoxytol in clinical practice: Implications for MRIJournal of Magnetic Resonance Imaging, 2012
- First‐pass contrast‐enhanced magnetic resonance angiography in humans using ferumoxytol, a novel ultrasmall superparamagnetic iron oxide (USPIO)‐based blood pool agentJournal of Magnetic Resonance Imaging, 2004
- MR angiography with an ultrasmall superparamagnetic iron oxide blood pool agentJournal of Magnetic Resonance Imaging, 1997